Dr. Esfandiari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9701 Richmond Ave
Houston, TX 77042
Education & Training
Azad UniversityClass of 2007
Publications & Presentations
PubMed
- 112 citationsNomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.Andrei Gafita, Jeremie Calais, Tristan Grogan, Boris Hadaschik, Hui Wang
The Lancet. Oncology. 2021-08-01 - 20 citationsSafety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen
Journal of Nuclear Medicine. 2021-10-01 - 37 citationsProspective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results...Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R Armstrong, Jeannine Gartmann
Journal of Nuclear Medicine. 2021-05-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
